{"database": "lobbying", "table": "lobbying_activities", "rows": [[2433403, "718772aa-eecf-4d8c-88bf-cd2fa3f455aa", "Q1", "WILLIAMS AND JENSEN, PLLC", 41454, "MERCK & CO INC", 2020, "first_quarter", "HCR", "Drug safety; Congressional oversight issues;  Issues related to vaccines and drug pricing; Drug pricing under 340B program; General education about FDA approval policies.  S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.  Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201  Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748  CARES Act, Public Law No: 116-136.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 80000, null, 0, 0, "2020-04-17T16:20:51.220000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2433403"], "units": {}, "query_ms": 0.3635589964687824, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}